AOD-9604
300 mcg · Daily
Evidence
- Human Studies
- 8
- Animal Studies
- 20
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Reasonably well-tolerated in the Phase 2 trials that were conducted, but those trials did not demonstrate the intended fat-loss benefit
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
AOD-9604 is a modified, more stable version of HGH Fragment 176-191, developed specifically to be tested as an anti-obesity drug. Its pharmaceutical development for that use was discontinued after Phase 2b trials failed to show a meaningful weight-loss benefit over placebo, though it was later approved in Australia as a novel food ingredient (not as a medicine).
Common Protocols
- 300 mcg subcutaneous daily, per informal research-community protocols — note the drug-development trials for weight loss specifically did not succeed
Side Effects
- Injection site irritation
- Generally reported as well-tolerated in the trials that were run
Interactions
- No formal interaction data exists
Practical Details
- Cost
- $$
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution
Research Links
Modified HGH fragment 176-191; approved as a novel food ingredient in Australia, not as a drug